Stenfilcon A

drug
On this page

Summary

Stenfilcon A (CHEMBL3039561) is a phase-3 clinical-stage small molecule.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Small molecule
  • Clinical trials: 11

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL3039561
NameStenfilcon A
TypeSmall molecule
Max phase3

Also known as: Stenfilcon a, STENFILCON A

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 11.

Phase distribution

PhaseTrials
Not specified11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01707238Not specifiedCOMPLETEDMulti-Centre Clinical Evaluation Of Two Daily Disposable Contact Lenses
NCT01808209Not specifiedCOMPLETEDClinical Performance of Stenfilcon A Versus Filcon II 3
NCT01809834Not specifiedCOMPLETEDEvaluation of Stenfilcon A Versus Etafilcon A
NCT02341859Not specifiedCOMPLETEDLens Fitting Evaluation of CooperVision MyDay™ Compared With 1-DAY ACUVUE® TruEye® and DAILIES TOTAL1®
NCT02366923Not specifiedCOMPLETEDDehydration of Stenfilcon A Contact Lenses Versus Delefilcon A Contact Lenses
NCT02510820Not specifiedCOMPLETEDThe Clinical Performance of the Biofinity Contact Lens (Comfilcon A) With Two Lens Care Systems
NCT02637804Not specifiedCOMPLETEDDaily Disposable Silicone Hydrogel Contact Lens, Stenfilcon A, Clinical Study
NCT02643004Not specifiedCOMPLETEDThe Clinical Comparison of Senofilcon A and Stenfilcon A Contact Lenses
NCT02801006Not specifiedCOMPLETEDThe Clinical Study of Silicone Hydrogel Daily Disposable Stenfilcon A Toric Lens
NCT02920970Not specifiedCOMPLETEDThe Clinical Comparison of Narafilcon A and Stenfilcon A Contact Lenses
NCT04005885Not specifiedCOMPLETEDA Clinical Comparison of Two Daily Disposable Soft Contact Lenses

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.